Skip to main content
Evidio Domingo-Musibay, MD, Oncology, Minneapolis, MN

EvidioDomingo-MusibayMD

Oncology Minneapolis, MN

Melanoma, Sarcoma

Medical Oncologist, Allina Health Cancer Institute

Dr. Domingo-Musibay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Domingo-Musibay's full profile

Already have an account?

  • Office

    800 E 28th St
    Ste 401
    Minneapolis, MN 55407
    Phone+1 612-863-0200
    Fax+1 612-863-0235

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2012 - 2015
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2009 - 2012
  • University of Minnesota Medical School
    University of Minnesota Medical SchoolClass of 2009
  • Columbia University
    Columbia UniversityM.A., Microbiology, 2001 - 2002
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsB.A., Biological Sciences, 2000

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2010 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • 28th Annual Short Course on Experimental Models of Human Cancer Jackson Laboratory, 2019
  • Merrill J. Egorin Workshop in Cancer Therapeutics and Drug Development Society for Translational Oncology (STO), 2014

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanc...
    Adi Diab, Mario Marcondes, Brian Kotzin, Mary Ann Tagliaferri, Ute Hoch, Yunfeng Li, Fiore Cattaruzza, Jonathan Zalevsky, Andrew Scott Brohl, James Brugarolas, Mehmet ..., 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, 3/1/2019
  • Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progressi...
    Amod Sarnaik, Sajeve Samuel Thomas, Diwakar Davar, John M. Kirkwood, Harriet Kluger, Jose Lutzky, Melissa Wilson, Anna C. Pavlick, Brendan Curti, Eric Whitman, Karl Le..., ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, 3/2019

Professional Memberships